Accueil >
Publications >
Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade

Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade

23 oct. 2019Science Translational Medicine

Auteurs

Tala Shekarian, Eva Sivado, Anne-Catherine Jallas, Stéphane Depil, Janice Kielbassa, Isabelle Janoueix-Lerosey, Gregor Hutter, Nadège Goutagny, Christophe Bergeron, Alain Viari, Sandrine Valsesia-Wittmann, Christophe Caux, Aurélien Marabelle

Résumé

Rotavirus vaccines have oncolytic properties and can overcome resistance to anti–PD-(L)1/CTLA-4 via RIG-I activation upon intratumoral administration.